Skip to main content
. 2022 Jun 14;9:866518. doi: 10.3389/fnut.2022.866518

TABLE 6.

Adverse events emerged during treatment period; different complications may have developed in the same patient.

References Gastrointestinal; treated patients, SOC Upper respiratory tract infection; treated patients, SOC CVC related complication; treated patients, SOC Pyrexia; treated patients, SOC Sepsis; treated patients, SOC Hepatobiliary/
pancreatic; treated patients, SOC
Electrolyte alterations; treated patients, SOC Dehydration; treated patients, SOC Cardiac decompensation; treated patients, SOC Injection site complications; treated patients, SOC Urinary complications; treated patients, SOC
Carter et al. (18)vw 21, 3 19, 3 13, 1 9, 2 3
Busoni et al. (19) 1 1
Ferreiro et al. (20)
Hill et al. (22)x 6 6
Kinberg (23)y 1 4
Lambe (25)z 1 2 2 1
Kocoshis et al. (24) 30, 7 15, 4 4 19, 4 5 9 4 3, 1
Martìnez et al. (26) 2 1 1 1
Ramos-Boluda et al. (16)z 1 1 1*
Ribeiro-Mourão et al. (15) 4 1
Rumbo et al. (17)
Sigalet et al. (9)
Sigalet et al. (12)v 2
Mercer et al. (21) 20 1 8 2
Total 87, 10 42, 7 19, 1 31, 6 1 16 4 10 1 10 4, 1

*Due to intercurrent disease; vAdverse events were described as not related to Tedugliutide; wComplications were described when occurring in > 5% of patients. xAdverse events were reported by 93.8% of patients, only 2 events were considered related to Teduglutide; yGastrointestinal complications were the most common event, but the paper did not include data; zAbdominal pain, stoma changes, redness at the injection site and legs and muscle pain are reported without specific data. SOC, Standard of Care; CVC, Central Vein Catheter.